All In Biotech

Drug Trial Radar · NCT07839936

A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of VERVE-102, a One-Time Dose Gene Editing Medicine, in Adults With or at High Risk for Atherosclerotic Cardiovascular Disease (ASCVD) Who Require Additional Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 175 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

175

Planned (sponsor's estimate)

Start

Sep 24, 2026

Primary completion

Aug 2028

Study completion Mar 2030

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Sep 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.

Conditions

  • Atherosclerosis
  • Cardiovascular Disease
  • Hypercholesterolemia

Interventions

  • VERVE-102Drug

    Administered IV

  • PlaceboDrug

    Administered IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change from Baseline in LDL-CTime frame: Baseline, Day 90

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Epic Medical Research

    DeSoto, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.